Repligen Corp（RGEN）股票分析RGENRepligen Corp

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its franchises include filtration, chromatography, process analytics and proteins. Its filtration franchise includes product offering covering upstream and downstream technologies. Its filtration products include XCell Alternating Tangential Flow (ATF) Cell Retention Systems, Flat Sheet Cassettes, Hollow Fiber Consumables, Tangential Flow Filtration Systems and Fluid Management. Its chromatography franchise includes products used in downstream purification, development, manufacturing and quality control of biological drugs. Its chromatography franchise includes OPUS Pre-Packed Columns, KRM Chromatography Systems and other additional chromatography products. Its process analytics include Downstream process analytical technology (PAT) and Upstream PAT. Its Proteins include Protein A Affinity Ligands, AVIPure Resins for New Modalities and Growth Factors. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Repligen Corp is currently priced at $176.93, which is below the analyst price target of $225 set by both Barclays and UBS. However, the stock has a high forward P/E ratio of 67.11, indicating that it may be overvalued at this price. The RSI is at 47.03, suggesting that the stock is neither overbought nor oversold. Given these factors, it may be wise to hold rather than buy at this moment, as the stock could face downward pressure if earnings do not meet expectations in the upcoming report on October 27, where the EPS estimate is $0.46.

6 analysts cover RGEN: 5 rate it Buy, 1 Hold and 0 Sell. The average price target is 189.00.